<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2013.1287</article-id>
<article-id pub-id-type="publisher-id">mmr-07-03-0811</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title><italic>Cyclin D1</italic> G870A polymorphism and risk of colorectal cancer: A case control study</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>SAMEER</surname><given-names>AGA SYED</given-names></name><xref rid="af1-mmr-07-03-0811" ref-type="aff">1</xref><xref rid="fn1-mmr-07-03-0811" ref-type="author-notes">7</xref></contrib>
<contrib contrib-type="author">
<name><surname>PARRAY</surname><given-names>FAZL Q.</given-names></name><xref rid="af2-mmr-07-03-0811" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>DAR</surname><given-names>MANZOOR AHMAD</given-names></name><xref rid="af2-mmr-07-03-0811" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>NISSAR</surname><given-names>SANIYA</given-names></name><xref rid="af1-mmr-07-03-0811" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>BANDAY</surname><given-names>MUJEEB ZAFAR</given-names></name><xref rid="af3-mmr-07-03-0811" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>RASOOL</surname><given-names>SABHA</given-names></name><xref rid="af5-mmr-07-03-0811" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author">
<name><surname>GULZAR</surname><given-names>G.M.</given-names></name><xref rid="af4-mmr-07-03-0811" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHOWDRI</surname><given-names>NISSAR A.</given-names></name><xref rid="af2-mmr-07-03-0811" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>SIDDIQI</surname><given-names>MUSHTAQ A.</given-names></name><xref rid="af1-mmr-07-03-0811" ref-type="aff">1</xref><xref rid="c1-mmr-07-03-0811" ref-type="corresp">6</xref></contrib></contrib-group>
<aff id="af1-mmr-07-03-0811">
<label>1</label>Department of Immunology and Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir</aff>
<aff id="af2-mmr-07-03-0811">
<label>2</label>Department of General Surgery, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir</aff>
<aff id="af4-mmr-07-03-0811">
<label>4</label>Department of Gastroenterology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir</aff>
<aff id="af3-mmr-07-03-0811">
<label>3</label>Department of Biotechnology, University of Kashmir, Hazratbal, Srinagar, Kashmir, India</aff>
<aff id="af5-mmr-07-03-0811">
<label>5</label>Department of Biochemistry, University of Kashmir, Hazratbal, Srinagar, Kashmir, India</aff>
<author-notes>
<corresp id="c1-mmr-07-03-0811"><italic>Correspondence to:</italic> Professor Mushtaq A Siddiqi, <sup>6</sup><italic>Present address:</italic> Transworld Muslim University, Parray Pora, Srinagar, Kashmir 190005, India, E-mail: <email>vc.tmuk@gmail.com</email></corresp><fn id="fn1-mmr-07-03-0811">
<p>Dr Aga Syed Sameer, <sup>7</sup><italic>Present address:</italic> Department of Biochemistry, Medical College, Sher-i-Kashmir Institute of Medical Sciences, Bemina, Srinagar, Kashmir 190018, India, E-mail: <email>mousvi786@gmail.com</email></p></fn></author-notes>
<pub-date pub-type="ppub">
<month>3</month>
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>01</month>
<year>2013</year></pub-date>
<volume>7</volume>
<issue>3</issue>
<fpage>811</fpage>
<lpage>815</lpage>
<history>
<date date-type="received">
<day>05</day>
<month>05</month>
<year>2012</year></date>
<date date-type="accepted">
<day>17</day>
<month>08</month>
<year>2012</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013, Spandidos Publications</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>The present study aimed to analyse the role of <italic>cyclin D1</italic> A870G polymorphism in modulating the susceptibility to colorectal cancer (CRC) in the Kashmiri population. The genotype distribution of the <italic>cyclin D1</italic> gene in 130 CRC cases in comparison with 160 healthy controls was investigated. No direct significant association between <italic>cyclin D1</italic> genotypes and CRC was observed; however, the AG and AA genotypes were found to be associated with an increased risk of CRC compared to the GG genotype, with an almost 2-fold increase in OR. This study suggests that the <italic>cyclin D1</italic> polymorphism is associated with an increased risk of CRC in the Kashmiri population.</p></abstract>
<kwd-group>
<kwd>colorectal cancer</kwd>
<kwd><italic>cyclin D1</italic></kwd>
<kwd>polymorphism</kwd>
<kwd>Kashmir</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p><italic>Cyclin D1</italic> (<italic>CCND1</italic>) is a key regulatory protein that plays a vital role in cell cycle control, particularly in the transition from G1 to S phase, which is regulated by cyclin-dependent kinases (<xref rid="b1-mmr-07-03-0811" ref-type="bibr">1</xref>). It results in the release of E2F transcription factors and allows cells to enter the S phase (<xref rid="b2-mmr-07-03-0811" ref-type="bibr">2</xref>).</p>
<p>Located on chromosome 11q13 (<xref rid="b3-mmr-07-03-0811" ref-type="bibr">3</xref>), the <italic>cyclin D1</italic> gene activation (due to amplification or chromosomal rearrangement), as well as its protein overexpression have been described in a wide variety of tumour types, including colon (<xref rid="b4-mmr-07-03-0811" ref-type="bibr">4</xref>&#x02013;<xref rid="b6-mmr-07-03-0811" ref-type="bibr">6</xref>), breast (<xref rid="b7-mmr-07-03-0811" ref-type="bibr">7</xref>,<xref rid="b8-mmr-07-03-0811" ref-type="bibr">8</xref>), head and neck (<xref rid="b9-mmr-07-03-0811" ref-type="bibr">9</xref>,<xref rid="b10-mmr-07-03-0811" ref-type="bibr">10</xref>) and lung (<xref rid="b11-mmr-07-03-0811" ref-type="bibr">11</xref>,<xref rid="b12-mmr-07-03-0811" ref-type="bibr">12</xref>) cancer, as its abnormal expression disrupts normal cell cycle control, hence possibly promoting the development and progression of cancer (<xref rid="b13-mmr-07-03-0811" ref-type="bibr">13</xref>).</p>
<p>Single nucleotide polymorphism (SNP) of <italic>cyclin D1</italic> at G870A has been studied in various cancers (<xref rid="b14-mmr-07-03-0811" ref-type="bibr">14</xref>&#x02013;<xref rid="b20-mmr-07-03-0811" ref-type="bibr">20</xref>), demonstrating its role in modulating the risk of cancers in different populations.</p>
<p>This common G to A polymorphism in the splice donor region of exon 4 in the <italic>cyclin D1</italic> gene located at codon 242 (nucleotide 870) is implicated on the splicing of the <italic>cyclin D1</italic> transcript (<xref rid="b14-mmr-07-03-0811" ref-type="bibr">14</xref>,<xref rid="b21-mmr-07-03-0811" ref-type="bibr">21</xref>). The dominant allele A preferentially transcribes the truncated transcript (transcript b), encoding a <italic>cyclin</italic> D1 protein with a longer half-life. The transcript b results in deregulated cell proliferation since it lacks a PEST sequence postulated to target for rapid degradation (<xref rid="b22-mmr-07-03-0811" ref-type="bibr">22</xref>). The higher levels of this protein may be associated with proliferation and a great risk of developing adenomas and cancer. The allele A, particularly in the homozygous state (AA genotype), has been associated with an increased risk of colorectal cancer (CRC) and adenomas, mostly in younger patients and in patients with family history of the illness (<xref rid="b23-mmr-07-03-0811" ref-type="bibr">23</xref>,<xref rid="b24-mmr-07-03-0811" ref-type="bibr">24</xref>). However, no association was found between the AG or GG genotypes (<xref rid="b25-mmr-07-03-0811" ref-type="bibr">25</xref>,<xref rid="b26-mmr-07-03-0811" ref-type="bibr">26</xref>) and others (<xref rid="b27-mmr-07-03-0811" ref-type="bibr">27</xref>,<xref rid="b28-mmr-07-03-0811" ref-type="bibr">28</xref>). The role of <italic>cyclin D1</italic> SNP in CRC risk remains controversial.</p>
<p>In the present case-control study we evaluated the potential impact of <italic>cyclin D1</italic> (G870A) gene polymorphism on the risk of CRC in the Kashmiri population. We also investigated whether or not there was a link between the clinicopathological variables of the <italic>cyclin D1</italic> variant genotype (AA), as well as its role in modulating the risk of CRC.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Population study</title>
<p>This study comprised 130 CRC cases. All the participants were patients of the Department of General Surgery of the Sher-I-Kashmir Institute of Medical Sciences in Kashmir. Blood samples were collected from 160 age- and gender-matched individuals, with no signs of any malignancy, serving as external controls. The mean age of both the patients and the control group was 53 years (<xref rid="tI-mmr-07-03-0811" ref-type="table">Table I</xref>).</p>
<p>Data on all CRC patients were obtained from personal interviews with patients and/or their guardian, as well as from their medical records. All patients and/or guardians were informed of the study and they provided written consent in the form of a pre-designed questionnaire (available on request). The collection and use of blood samples (from patients and controls) for this study was approved by the appropriate institutional ethics committee.</p></sec>
<sec>
<title>DNA extraction and polymerase chain reaction (PCR)</title>
<p>DNA extraction was performed using the ammonium precipitation method. Genotyping for the <italic>cyclin D1</italic> A870G polymorphism was determined by the method described previously by Satinder <italic>et al</italic>(<xref rid="b3-mmr-07-03-0811" ref-type="bibr">3</xref>). The oligonucleotide primers used for the amplification of the target region were: forward 5&#x02032;-AGT TCATTTCCAATCCGCCC-3&#x02032; and reverse 5&#x02032;-TTTCCGTGGCACTAGGTGTC-3&#x02032;. PCR was carried out in a final volume of 20 &#x003BC;l, containing 50 ng genomic DNA template, 1X PCR buffer (Fermentas, MD, USA), with 2 mM MgCl<sub>2</sub>, 0.5 &#x003BC;M of each primer (Sigma-Aldrich, Bangalore, India), 50 &#x003BC;M deoxynucleotide triphosphates (dNTPs) (Cinnagen, Tehran, Iran) and 0.25 units of Taq DNA polymerase (Invitrogen, Bangalore, India). For PCR amplification, the standard program was used as follows: one initial denaturation step at 94&#x000B0;C for 7 min, followed by 40 denaturation cycles of 30 sec at 94&#x000B0;C, 30 sec of annealing at 60&#x000B0;C and 30 sec of extension at 72&#x000B0;C for 40 cycles, followed by a final elongation cycle at 72&#x000B0;C for 7 min.</p>
<p>The PCR product of <italic>cyclin D1</italic> was 212 bp in length and was then digested with 2 units of <italic>MspI</italic> in a reaction mixture of 20 &#x003BC;l for 3 h at 37&#x000B0;C. The digestion resulted in the generation of 3 bands of 141, 37 and 34 bp for the wild genotype (GG), whereas for the homozygous variant genotype (AA) 2 bands of 175 and 37 bp were produced (<xref rid="f1-mmr-07-03-0811" ref-type="fig">Fig. 1</xref>).</p>
<p>DNA amplicons, as well as the digestion products, were electrophoresed through a 2&#x02013;3&#x00025; agarose gel (Genie, Bangalore, India) for resolution. The genotypes of &gt;20&#x00025; of the samples were reassessed in a double-blind manner by 2 independent researchers to confirm the results. A positive control for each polymorphism was used for 50&#x00025; of the samples.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>The observed frequencies of genotypes in CRC patients were compared with controls using Chi-square or Fisher&#x02019;s exact (FET) tests, when the expected frequencies were small. The Chi-square test was used to verify whether or not the genotype distributions were in Hardy-Weinberg equilibrium. P&#x02264;0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using PASW version 18 software.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>The present study comprised 130 CRC cases and 160 control subjects</title>
<p>The patients comprised 76 males and 54 females (M/F ratio&#x0003D;1.41), while the control subjects were 88 males and 72 females (M/F ratio&#x0003D;1.2). The mean age in the patient and control groups was 52 years. No significant gender- or age-related differences were observed between the groups (p&gt;0.05). Furthermore, out of 130 confirmed cases of CRC, 125 cases were sporadic, 4 were familial adenomatous polyposis and one case was hereditary non-polyposis (Lynch Syndrome) CRC. All but one case had adenocarcinoma, one had squamous cell carcinoma of the basal cell type, and 52 had carcinoma in the colon, while 78 had carcinoma in the rectum. A total of 78 resided in rural areas, while 39 resided in urban areas; 81 were smokers and 49 non-smokers (<xref rid="tI-mmr-07-03-0811" ref-type="table">Table I</xref>).</p>
<p>Among the CRC cases, we found the frequency of the <italic>cyclin D1</italic> genotype to be 14.61&#x00025; (19/130) for GG, 53.85&#x00025; (70/130) for AG and 31.54&#x00025; (41/130) for AA, while the frequency in the general control population was 25.62&#x00025; (41/160) for GG, 47.50&#x00025; (76/160) for AG and 26.88&#x00025; (43/160) for AA. The overall association between the <italic>cyclin D1</italic> polymorphism and the CRC cases was found to be non-significant (p&gt;0.05; <xref rid="tII-mmr-07-03-0811" ref-type="table">Table II</xref>). However, a separate analysis for the AG and AA genotypes revealed a marked association with the risk of CRC (p&lt;0.05). The overall hazard ratio of the <italic>cyclin D1</italic> A allele in CRC was 2.01 (95&#x00025; CI&#x0003D;1.10&#x02013;3.68).</p>
<p>The correlation between the <italic>cyclin D1</italic> polymorphic status and the clinicopathological characteristics was also carefully analysed. A marked association (p&lt;0.05) was observed among the A allele, age and dwelling (p&lt;0.05; <xref rid="tIII-mmr-07-03-0811" ref-type="table">Table III</xref>), while the remaining parameters were not found to be markedly associated with the variant A allele of the <italic>cyclin D1</italic> gene.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The Kashmiri population is exposed to a special set of environmental and dietary risks, such as exposure to nitroso compounds or amines and nitrates reported to be present in local foodstuffs, most of which have been shown to contain important irritants and carcinogens (<xref rid="b29-mmr-07-03-0811" ref-type="bibr">29</xref>&#x02013;<xref rid="b32-mmr-07-03-0811" ref-type="bibr">32</xref>).</p>
<p>CRC is the third most common cancer in males and the second in females worldwide (<xref rid="b33-mmr-07-03-0811" ref-type="bibr">33</xref>). In the Kashmir valley, it represents the third most common gastrointestinal tract (GIT) cancer, following oesophageal and gastric cancer (<xref rid="b30-mmr-07-03-0811" ref-type="bibr">30</xref>,<xref rid="b31-mmr-07-03-0811" ref-type="bibr">31</xref>,<xref rid="b34-mmr-07-03-0811" ref-type="bibr">34</xref>).</p>
<p>The <italic>cyclin D1</italic> A870G polymorphism has 3 distinct genotypes: GG (wild-type), AG and AA (variants). All 3 forms synthesise similar proteins due to their identical biological functionality. However, the difference among the genotypes is the capability of A allele to cause the truncation of the transcript, which in turn increases the half-life of the resulting protein (<xref rid="b1-mmr-07-03-0811" ref-type="bibr">1</xref>,<xref rid="b28-mmr-07-03-0811" ref-type="bibr">28</xref>).</p>
<p>In the present study, we investigated the association between the <italic>cyclin D1</italic> A870G polymorphism and CRC in the Kashmiri population. Although no association was found between this polymorphism and the risk of CRC, our results demonstrated a statistically significant (p&lt;0.05) 1.99-fold increase in the OR for the AG genotype and a 2.05-fold increase in the OR for the AA genotype (<xref rid="tII-mmr-07-03-0811" ref-type="table">Table II</xref>), when compared to the GG genotype. Furthermore, there was a statistically significant (p&lt;0.05) 2.01-fold increase in the OR for the A allele in a dominant model of inheritance, although only a 1.25-fold increase in the OR for the A allele in a recessive model of inheritance. These results are quite different from those of Jian <italic>et al</italic>(<xref rid="b25-mmr-07-03-0811" ref-type="bibr">25</xref>), who reported a recessive model of inheritance for this polymorphism in the Indian population on the basis of high fold increase in OR (1.56). The frequency of the different genotypes of <italic>cyclin D1</italic> polymorphism in our Kashmiri CRC cases was 14.61&#x00025; (19/130) for the GG, 53.85&#x00025; (70/130) for the AG and 31.54&#x00025; (41/130) for the AA genotype. The frequencies for the rest of Indian population reported by Jian <italic>et al</italic> were 5.28&#x00025; (46/301) for the GG, 43.19&#x00025; (130/301) for the AG and 41.52&#x00025; (125/301) for the AA genotype. The differences between the Kashmiri and the Indian populations may be due to the fact that the former belongs to the Persian genotypic pool, having descended from Persian migrants settled in the Kashmir valley during the 15th century. However, the present study was consistent with a Brazilian study regarding the frequencies of the 3 genotypes of <italic>cyclin D1</italic> A870G polymorphism (<xref rid="b28-mmr-07-03-0811" ref-type="bibr">28</xref>). Moreover, consistent with our findings, results supporting the dominant model of inheritance have been reported by Tan <italic>et al</italic>(<xref rid="b35-mmr-07-03-0811" ref-type="bibr">35</xref>).</p>
<p>Zheng <italic>et al</italic>(<xref rid="b17-mmr-07-03-0811" ref-type="bibr">17</xref>) previously reported the frequency of the AA genotype to be higher in patients with squamous cell carcinoma of the head and neck (SCCHN) (23.6&#x00025;) compared to controls (16.5&#x00025;) in a non-hispanic white population, and concluded beyond doubt that the subjects with the AA genotype had a higher probability of developing SCCHN at an earlier stage than those with the GG genotype. However, in the present study we found quite the reverse. Subsequent to statistical analysis of the data using clinicopathological parameters (<xref rid="tIII-mmr-07-03-0811" ref-type="table">Table III</xref>), a significant association of the AA genotype with the older age group (&gt;50 years) was observed (p&lt;0.05), demonstrating that older patients were at a higher risk of developing CRC, compared to younger ones. These results are also contradictory to those reported by Huang <italic>et al</italic> in the Taiwanese population (<xref rid="b36-mmr-07-03-0811" ref-type="bibr">36</xref>). The AA genotype was also found to be markedly associated with dwelling, suggesting that rural dwellers were at increased risk of CRC.</p>
<p>In a recent meta-analysis by Zhang <italic>et al</italic>(<xref rid="b37-mmr-07-03-0811" ref-type="bibr">37</xref>) it was determined that the A allele significantly elevated the risk of CRC in co-dominant and dominant models. This supports our own observations from the present study. Furthermore, on the basis of ethnic stratification, significant associations were found in Caucasian populations, although not in Asians, thereby suggesting a possible role of ethnic differences in genetic background in addition to environmental factors (<xref rid="b38-mmr-07-03-0811" ref-type="bibr">38</xref>,<xref rid="b39-mmr-07-03-0811" ref-type="bibr">39</xref>).</p>
<p>Pabalan <italic>et al</italic> reported in a meta-analysis on all cancers that the <italic>cyclin D1</italic> G870A polymorphism confers susceptibility to cancer development, irrespective of the population studied (<xref rid="b40-mmr-07-03-0811" ref-type="bibr">40</xref>). Its interaction with other genetic variants and environmental factors was also observed to have resulted in an elevated risk of cancer (OR, 1.6&#x02013;7.1).</p>
<p>Furthermore, the interaction between polymorphism and various environmental factors induces and increases the overall susceptibility to CRC in any population (<xref rid="b37-mmr-07-03-0811" ref-type="bibr">37</xref>&#x02013;<xref rid="b39-mmr-07-03-0811" ref-type="bibr">39</xref>). Therefore, we also suggest that since the Kashmiri population is exposed to a special set of environmental and dietary risks, which include the consumption of sun-dried and smoked fish and meat, dried and pickled vegetables, red chilli, hakh (a leafy vegetable of the Brassica family), hot noon chai (salted tea) and hukka (water pipe) smoke (<xref rid="b30-mmr-07-03-0811" ref-type="bibr">30</xref>&#x02013;<xref rid="b32-mmr-07-03-0811" ref-type="bibr">32</xref>), this may play a significant role in modulating the effect of polymorphism on the dominant model of inheritance. The etiology and incidence of various GIT cancers in the Kashmiri population has been previously reported to be attributed to probable exposure to nitroso compounds, amines and nitrates that are present in local foodstuffs, most of which have been proven to contain notable irritants and carcinogens (<xref rid="b29-mmr-07-03-0811" ref-type="bibr">29</xref>).</p>
<p>In conclusion, we found a clear association between the <italic>cyclin D1</italic> A870G polymorphism and the risk of CRC in the ethnic Kashmiri population. Nevertheless, these correlations need to be verified in a large-scale study, in order to discern racial differences and determine the aggressiveness of CRC.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors gratefully acknowledge the financial support provided by the Sher-I-Kashmir Institute of Medical Sciences, and would also like to thank the head and technical staff of the operating theatre at the Department of General Surgery of the Sher-I-Kashmir Institute of Medical Sciences, for their assistance with tissue procurement. The authors also thank the anonymous pathologists at the Department of Pathology of the Sher-I-Kashmir Institute of Medical Sciences for their histopathological assessment of the tumour tissues.</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-mmr-07-03-0811"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Cancer cell cycles</article-title><source>Science</source><volume>274</volume><fpage>1672</fpage><lpage>1677</lpage><year>1996</year></element-citation></ref>
<ref id="b2-mmr-07-03-0811"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name></person-group><article-title>Living with or without cyclins and cyclin-dependent kinases</article-title><source>Genes Dev</source><volume>18</volume><fpage>2699</fpage><lpage>2711</lpage><year>2004</year></element-citation></ref>
<ref id="b3-mmr-07-03-0811"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satinder</surname><given-names>K</given-names></name><name><surname>Chander</surname><given-names>SR</given-names></name><name><surname>Pushpinder</surname><given-names>K</given-names></name><name><surname>Indu</surname><given-names>G</given-names></name><name><surname>Veena</surname><given-names>J</given-names></name></person-group><article-title>Cyclin D1 (G870A) polymorphism and risk of cervix cancer: A case control study in north Indian population</article-title><source>Mol Cell Biochem</source><volume>315</volume><fpage>151</fpage><lpage>157</lpage><year>2008</year></element-citation></ref>
<ref id="b4-mmr-07-03-0811"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartkova</surname><given-names>J</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name></person-group><article-title>The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas</article-title><source>Int J Cancer</source><volume>58</volume><fpage>568</fpage><lpage>573</lpage><year>1994</year></element-citation></ref>
<ref id="b5-mmr-07-03-0811"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arber</surname><given-names>N</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Moss</surname><given-names>SF</given-names></name><name><surname>Sutter</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Begg</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name><name><surname>Holt</surname><given-names>PR</given-names></name></person-group><article-title>Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis</article-title><source>Gastroenterology</source><volume>110</volume><fpage>669</fpage><lpage>674</lpage><year>1996</year></element-citation></ref>
<ref id="b6-mmr-07-03-0811"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Onoda</surname><given-names>N</given-names></name><name><surname>Nishiguchi</surname><given-names>Y</given-names></name><name><surname>Ikehara</surname><given-names>T</given-names></name><name><surname>Nakata</surname><given-names>B</given-names></name><name><surname>Okuno</surname><given-names>M</given-names></name><name><surname>Sowa</surname><given-names>M</given-names></name></person-group><article-title>Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma</article-title><source>Oncology</source><volume>55</volume><fpage>145</fpage><lpage>151</lpage><year>1998</year></element-citation></ref>
<ref id="b7-mmr-07-03-0811"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Gregory</surname><given-names>W</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Millis</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Barnes</surname><given-names>D</given-names></name></person-group><article-title>Cyclin D1 and prognosis in human breast cancer</article-title><source>Int J Cancer</source><volume>69</volume><fpage>92</fpage><lpage>99</lpage><year>1996</year></element-citation></ref>
<ref id="b8-mmr-07-03-0811"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>KL</given-names></name><name><surname>Varley</surname><given-names>JM</given-names></name></person-group><article-title>Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry</article-title><source>Br J Cancer</source><volume>77</volume><fpage>1460</fpage><lpage>1468</lpage><year>1998</year></element-citation></ref>
<ref id="b9-mmr-07-03-0811"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>T</given-names></name><name><surname>el-Naggar</surname><given-names>AK</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Frankenthaler</surname><given-names>R</given-names></name><name><surname>Luna</surname><given-names>MA</given-names></name><name><surname>Batsakis</surname><given-names>JG</given-names></name></person-group><article-title>PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma</article-title><source>Cancer</source><volume>74</volume><fpage>152</fpage><lpage>158</lpage><year>1994</year></element-citation></ref>
<ref id="b10-mmr-07-03-0811"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jares</surname><given-names>P</given-names></name><name><surname>Fern&#x000E1;ndez</surname><given-names>PL</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Nadal</surname><given-names>A</given-names></name><name><surname>Bosch</surname><given-names>F</given-names></name><name><surname>Aiza</surname><given-names>G</given-names></name><name><surname>Nayach</surname><given-names>I</given-names></name><name><surname>Traserra</surname><given-names>J</given-names></name><name><surname>Cardesa</surname><given-names>A</given-names></name></person-group><article-title>PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas</article-title><source>Cancer Res</source><volume>54</volume><fpage>4813</fpage><lpage>4817</lpage><year>1994</year></element-citation></ref>
<ref id="b11-mmr-07-03-0811"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betticher</surname><given-names>DC</given-names></name><name><surname>Heighway</surname><given-names>J</given-names></name><name><surname>Hasleton</surname><given-names>PS</given-names></name><name><surname>Altermatt</surname><given-names>HJ</given-names></name><name><surname>Ryder</surname><given-names>WD</given-names></name><name><surname>Cerny</surname><given-names>T</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name></person-group><article-title>Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small cell lung cancer</article-title><source>Br J Cancer</source><volume>73</volume><fpage>294</fpage><lpage>300</lpage><year>1996</year></element-citation></ref>
<ref id="b12-mmr-07-03-0811"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Edwards</surname><given-names>CD</given-names></name><name><surname>Kobzik</surname><given-names>L</given-names></name><name><surname>Godleski</surname><given-names>J</given-names></name><name><surname>Richards</surname><given-names>W</given-names></name><name><surname>Sugarbaker</surname><given-names>DJ</given-names></name><name><surname>Rollins</surname><given-names>BJ</given-names></name></person-group><article-title>Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines</article-title><source>Cancer Res</source><volume>55</volume><fpage>505</fpage><lpage>509</lpage><year>1995</year></element-citation></ref>
<ref id="b13-mmr-07-03-0811"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Weghorst</surname><given-names>CM</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><article-title>Overexpression of cyclin D1 enhances gene amplification</article-title><source>Cancer Res</source><volume>56</volume><fpage>36</fpage><lpage>39</lpage><year>1996</year></element-citation></ref>
<ref id="b14-mmr-07-03-0811"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkiz</surname><given-names>H</given-names></name><name><surname>Bayram</surname><given-names>S</given-names></name><name><surname>Bekar</surname><given-names>A</given-names></name><name><surname>Akg&#x000F6;ll&#x000FC;</surname><given-names>E</given-names></name><name><surname>Ozdil</surname><given-names>B</given-names></name></person-group><article-title>Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study</article-title><source>Cancer Epidemiol</source><volume>34</volume><fpage>298</fpage><lpage>302</lpage><year>2010</year></element-citation></ref>
<ref id="b15-mmr-07-03-0811"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>YK</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Chang</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Cyclin D1 genotype in areca-associated oral squamous cell carcinoma</article-title><source>J Oral Pathol Med</source><volume>32</volume><fpage>265</fpage><lpage>270</lpage><year>2003</year></element-citation></ref>
<ref id="b16-mmr-07-03-0811"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>NH</given-names></name><name><surname>Song</surname><given-names>YS</given-names></name><name><surname>Kang</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>HP</given-names></name></person-group><article-title>Cyclin D1 polymorphism and the risk of endometrial cancer</article-title><source>Gynecol Oncol</source><volume>97</volume><fpage>431</fpage><lpage>435</lpage><year>2005</year></element-citation></ref>
<ref id="b17-mmr-07-03-0811"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Sturgis</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: A case-control study</article-title><source>Carcinogenesis</source><volume>22</volume><fpage>1195</fpage><lpage>1199</lpage><year>2001</year></element-citation></ref>
<ref id="b18-mmr-07-03-0811"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Luthra</surname><given-names>R</given-names></name><name><surname>Lynch</surname><given-names>PM</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name><name><surname>Frazier</surname><given-names>ML</given-names></name></person-group><article-title>Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer</article-title><source>Cancer Res</source><volume>60</volume><fpage>249</fpage><lpage>252</lpage><year>2000</year></element-citation></ref>
<ref id="b19-mmr-07-03-0811"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catarino</surname><given-names>R</given-names></name><name><surname>Matos</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism</article-title><source>Cancer Genet Cytogenet</source><volume>160</volume><fpage>49</fpage><lpage>54</lpage><year>2005</year></element-citation></ref>
<ref id="b20-mmr-07-03-0811"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>N</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Kohaar</surname><given-names>I</given-names></name><etal/></person-group><article-title>Genetic variant of CCND1: Association with HPV-mediated cervical cancer in Indian population</article-title><source>Biomarkers</source><volume>14</volume><fpage>219</fpage><lpage>225</lpage><year>2009</year></element-citation></ref>
<ref id="b21-mmr-07-03-0811"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betticher</surname><given-names>DC</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Altermatt</surname><given-names>HJ</given-names></name><name><surname>Hoban</surname><given-names>P</given-names></name><name><surname>Ryder</surname><given-names>WDJ</given-names></name><name><surname>Heighway</surname><given-names>J</given-names></name></person-group><article-title>Alternate splicing produces a novel cyclin D1 transcript</article-title><source>Oncogene</source><volume>11</volume><fpage>1005</fpage><lpage>1011</lpage><year>1995</year></element-citation></ref>
<ref id="b22-mmr-07-03-0811"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawa</surname><given-names>H</given-names></name><name><surname>Ohshima</surname><given-names>TA</given-names></name><name><surname>Ukita</surname><given-names>H</given-names></name><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>Y</given-names></name><name><surname>Kamada</surname><given-names>H</given-names></name><etal/></person-group><article-title>Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner</article-title><source>Oncogene</source><volume>16</volume><fpage>1701</fpage><lpage>1712</lpage><year>1998</year></element-citation></ref>
<ref id="b23-mmr-07-03-0811"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Lynch</surname><given-names>PM</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name><name><surname>Zong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cyclin D1 polymorphism and increased risk of colorectal cancer at young age</article-title><source>J Natl Cancer Inst</source><volume>93</volume><fpage>1106</fpage><lpage>1108</lpage><year>2001</year></element-citation></ref>
<ref id="b24-mmr-07-03-0811"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>TR</given-names></name><name><surname>Richards</surname><given-names>FM</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Jankowski</surname><given-names>JA</given-names></name><name><surname>Macdonald</surname><given-names>F</given-names></name><etal/></person-group><article-title>Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer</article-title><source>Oncogene</source><volume>21</volume><fpage>1928</fpage><lpage>1933</lpage><year>2002</year></element-citation></ref>
<ref id="b25-mmr-07-03-0811"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Gajalakshmi</surname><given-names>V</given-names></name><name><surname>Kuriki</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Akasaka</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Tokudome</surname><given-names>S</given-names></name></person-group><article-title>Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population</article-title><source>J Cancer Res Clin Oncol</source><volume>132</volume><fpage>193</fpage><lpage>199</lpage><year>2006</year></element-citation></ref>
<ref id="b26-mmr-07-03-0811"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaylim-Eraltan</surname><given-names>I</given-names></name><name><surname>Arikan</surname><given-names>S</given-names></name><name><surname>Yildiz</surname><given-names>Y</given-names></name><name><surname>Cacina</surname><given-names>C</given-names></name><name><surname>Ergen</surname><given-names>HA</given-names></name><name><surname>Tuna</surname><given-names>G</given-names></name><name><surname>G&#x000F6;rm&#x000FC;s</surname><given-names>U</given-names></name><name><surname>Zeybek</surname><given-names>U</given-names></name><name><surname>Isbir</surname><given-names>T</given-names></name></person-group><article-title>The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population</article-title><source>Anticancer Res</source><volume>30</volume><fpage>2875</fpage><lpage>2880</lpage><year>2010</year></element-citation></ref>
<ref id="b27-mmr-07-03-0811"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>JA</given-names></name><name><surname>Douglas</surname><given-names>JJ</given-names></name><name><surname>Ross</surname><given-names>VG</given-names></name><name><surname>Curran</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>GI</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cyclin D1 protein expression and gene polymorphism in colorectal cancer</article-title><source>Int J Cancer</source><volume>88</volume><fpage>77</fpage><lpage>81</lpage><year>2000</year></element-citation></ref>
<ref id="b28-mmr-07-03-0811"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forones</surname><given-names>NM</given-names></name><name><surname>de Lima</surname><given-names>JM</given-names></name><name><surname>de Souza</surname><given-names>LG</given-names></name><name><surname>da Silva</surname><given-names>ID</given-names></name></person-group><article-title>Cyclin D1 A870G polymorphism in Brazilian colorectal cancer patients</article-title><source>J Gastrointest Cancer</source><volume>39</volume><fpage>118</fpage><lpage>123</lpage><year>2008</year></element-citation></ref>
<ref id="b29-mmr-07-03-0811"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Fazili</surname><given-names>Z</given-names></name><name><surname>Spiegelhalder</surname><given-names>B</given-names></name><name><surname>Preussmann</surname><given-names>R</given-names></name></person-group><article-title>Increased exposure to dietary amines and nitrate in a population at high risk of oesophageal and gastric cancer in Kashmir (India)</article-title><source>Carcinogenesis</source><volume>13</volume><fpage>1331</fpage><lpage>1335</lpage><year>1992</year></element-citation></ref>
<ref id="b30-mmr-07-03-0811"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sameer</surname><given-names>AS</given-names></name><name><surname>Nissar</surname><given-names>S</given-names></name><name><surname>Abdullah</surname><given-names>S</given-names></name><name><surname>Chowdri</surname><given-names>NA</given-names></name><name><surname>Siddiqi</surname><given-names>MA</given-names></name></person-group><article-title>DNA repair gene 8-oxoguanine DNA glycosylase Ser326Cys polymorphism and colorectal cancer risk in a Kashmiri population</article-title><source>DNA Cell Biol</source><volume>31</volume><fpage>541</fpage><lpage>546</lpage><year>2012</year></element-citation></ref>
<ref id="b31-mmr-07-03-0811"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sameer</surname><given-names>AS</given-names></name><name><surname>Shah</surname><given-names>ZA</given-names></name><name><surname>Nissar</surname><given-names>S</given-names></name><name><surname>Mudassar</surname><given-names>S</given-names></name><name><surname>Siddiqi</surname><given-names>MA</given-names></name></person-group><article-title>Risk of colorectal cancer associated with the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the Kashmiri population</article-title><source>Genet Mol Res</source><volume>10</volume><fpage>1200</fpage><lpage>1210</lpage><year>2011</year></element-citation></ref>
<ref id="b32-mmr-07-03-0811"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasool</surname><given-names>S</given-names></name><name><surname>Ganai</surname><given-names>BA</given-names></name><name><surname>Kadla</surname><given-names>SA</given-names></name><name><surname>Ahanger</surname><given-names>AG</given-names></name><name><surname>Qazi</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Rasool</surname><given-names>V</given-names></name><name><surname>Masood</surname><given-names>A</given-names></name></person-group><article-title>The ECRG1 290Arg/Gln polymorphism is related to risk of esophageal squamous cell carcinoma in Kashmir</article-title><source>Asian Pac J Cancer Prev</source><volume>12</volume><fpage>265</fpage><lpage>269</lpage><year>2011</year></element-citation></ref>
<ref id="b33-mmr-07-03-0811"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><volume>61</volume><fpage>69</fpage><lpage>90</lpage><year>2011</year></element-citation></ref>
<ref id="b34-mmr-07-03-0811"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javid</surname><given-names>G</given-names></name><name><surname>Zargar</surname><given-names>SA</given-names></name><name><surname>Rather</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>AR</given-names></name><name><surname>Khan</surname><given-names>BA</given-names></name><name><surname>Yattoo</surname><given-names>GN</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Gulzar</surname><given-names>GM</given-names></name><name><surname>Sodhi</surname><given-names>JS</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Shoukat-Deeba Bashir</surname><given-names>A</given-names></name></person-group><article-title>Incidence of colorectal cancer in Kashmir valley, India</article-title><source>Indian J Gastroenterol</source><volume>30</volume><fpage>7</fpage><lpage>11</lpage><year>2011</year></element-citation></ref>
<ref id="b35-mmr-07-03-0811"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>XL</given-names></name><name><surname>Nieters</surname><given-names>A</given-names></name><name><surname>Kropp</surname><given-names>S</given-names></name><etal/></person-group><article-title>The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis</article-title><source>Int J Cancer</source><volume>122</volume><fpage>2573</fpage><lpage>2580</lpage><year>2008</year></element-citation></ref>
<ref id="b36-mmr-07-03-0811"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>WS</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>PY</given-names></name><name><surname>Changchien</surname><given-names>CR</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Chiang</surname><given-names>JM</given-names></name><name><surname>Yeh</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Hsieh</surname><given-names>LL</given-names></name></person-group><article-title>Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectalcancer in Taiwan</article-title><source>Dis Colon Rectum</source><volume>49</volume><fpage>602</fpage><lpage>608</lpage><year>2006</year></element-citation></ref>
<ref id="b37-mmr-07-03-0811"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LQ</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>JQ</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>FY</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>JN</given-names></name></person-group><article-title>The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: A meta-analysis of 20 populations</article-title><source>Asian Pac J Cancer Prev</source><volume>12</volume><fpage>81</fpage><lpage>85</lpage><year>2011</year></element-citation></ref>
<ref id="b38-mmr-07-03-0811"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnellan</surname><given-names>R</given-names></name><name><surname>Chetty</surname><given-names>R</given-names></name></person-group><article-title>Cyclin D1 and human neoplasia</article-title><source>Mol Pathol</source><volume>51</volume><fpage>1</fpage><lpage>7</lpage><year>1998</year></element-citation></ref>
<ref id="b39-mmr-07-03-0811"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmqvist</surname><given-names>R</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Oberg</surname><given-names>A</given-names></name><etal/></person-group><article-title>Expression of cyclin D1 and retinoblastoma protein in colorectal cancer</article-title><source>Eur J Cancer</source><volume>34</volume><fpage>1575</fpage><lpage>1581</lpage><year>1998</year></element-citation></ref>
<ref id="b40-mmr-07-03-0811"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pabalan</surname><given-names>N</given-names></name><name><surname>Bapat</surname><given-names>B</given-names></name><name><surname>Sung</surname><given-names>L</given-names></name><name><surname>Jarjanazi</surname><given-names>H</given-names></name><name><surname>Pabalan</surname><given-names>OF</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name></person-group><article-title>Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: A meta-analysis</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>17</volume><fpage>2773</fpage><lpage>2781</lpage><year>2008</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-07-03-0811" position="float">
<label>Figure 1</label>
<caption>
<p>Representative gel of <italic>cyclin D1</italic> A870G polymorphism, representing amplicon digest with MspI (C|CGG), where variant (AA) is cleaved to generate a visible 175-bp band and wild-type (GG) is cleaved to generate a visible 141-bp band. Lanes: M, 50-bp ladder; 3, 8, 11 and 12, homozygous wild-type (GG) form; 1, 2, 4, 5, 6, 7 and 10, heterozygous (AG) form; 9, homozygous (AA) variant form.</p></caption>
<graphic xlink:href="MMR-07-03-0811-g00.gif"/></fig>
<table-wrap id="tI-mmr-07-03-0811" position="float">
<label>Table I</label>
<caption>
<p>Demographic and clinical characteristics of study subjects.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Variable</th>
<th align="center" valign="top">CRC cases (n&#x0003D;130)</th>
<th align="center" valign="top">Healthy controls (n&#x0003D;160)</th>
<th align="center" valign="top">P-value</th></tr></thead>
<tbody>
<tr>
<td colspan="4" align="left" valign="top">Age group</td></tr>
<tr>
<td align="left" valign="top">&#x02003;&#x02264;50</td>
<td align="center" valign="top">48 (36.9&#x00025;)</td>
<td align="center" valign="top">56 (35.0&#x00025;)</td>
<td align="center" valign="top">0.80</td></tr>
<tr>
<td align="left" valign="top">&#x02003;&gt;50</td>
<td align="center" valign="top">82 (63.1&#x00025;)</td>
<td align="center" valign="top">104 (65.0&#x00025;)</td>
<td align="center" valign="top"/></tr>
<tr>
<td colspan="4" align="left" valign="top">Gender</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Female</td>
<td align="center" valign="top">54 (41.54&#x00025;)</td>
<td align="center" valign="top">72 (45.0&#x00025;)</td>
<td align="center" valign="top">0.63</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Male</td>
<td align="center" valign="top">76 (58.46&#x00025;)</td>
<td align="center" valign="top">88 (55.0&#x00025;)</td>
<td align="center" valign="top"/></tr>
<tr>
<td colspan="4" align="left" valign="top">Dwelling</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Rural</td>
<td align="center" valign="top">91 (70.0&#x00025;)</td>
<td align="center" valign="top">104 (65.0&#x00025;)</td>
<td align="center" valign="top">0.38</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Urban</td>
<td align="center" valign="top">39 (30.0&#x00025;)</td>
<td align="center" valign="top">56 (35.0&#x00025;)</td>
<td align="center" valign="top"/></tr>
<tr>
<td colspan="4" align="left" valign="top">Smoking status</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Ever</td>
<td align="center" valign="top">81 (62.3&#x00025;)</td>
<td align="center" valign="top">90 (56.3&#x00025;)</td>
<td align="center" valign="top">0.33</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Never</td>
<td align="center" valign="top">49 (37.7&#x00025;)</td>
<td align="center" valign="top">70 (43.7&#x00025;)</td>
<td align="center" valign="top"/></tr>
<tr>
<td colspan="4" align="left" valign="top">Tumour location</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Colon</td>
<td align="center" valign="top">52 (40.0&#x00025;)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Rectum</td>
<td align="center" valign="top">78 (60.0&#x00025;)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/></tr>
<tr>
<td colspan="4" align="left" valign="top">Tumour grade</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Well-differentiated</td>
<td align="center" valign="top">98 (75.4&#x00025;)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Moderately/poorly differentiated</td>
<td align="center" valign="top">32 (24.6&#x00025;)</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/></tr></tbody></table></table-wrap>
<table-wrap id="tII-mmr-07-03-0811" position="float">
<label>Table II</label>
<caption>
<p>Genotype frequencies of <italic>cyclin D1</italic> gene polymorphism in CRC cases and controls.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top"><italic>Cyclin D1</italic> genotype</th>
<th align="center" valign="top">CRC cases (n&#x0003D; 130)</th>
<th align="center" valign="top">Controls (n&#x0003D;160)</th>
<th align="center" valign="top">OR (95&#x00025; CI) P<xref rid="tfn1-mmr-07-03-0811" ref-type="table-fn">a</xref>,F<xref rid="tfn2-mmr-07-03-0811" ref-type="table-fn">b</xref></th>
<th align="center" valign="top">P-value (overall)</th></tr></thead>
<tbody>
<tr>
<td colspan="5" align="left" valign="top">Co-dominant inheritance</td></tr>
<tr>
<td align="left" valign="top">GG (wild)</td>
<td align="right" valign="top">19 (14.6&#x00025;)</td>
<td align="center" valign="top">41 (25.6&#x00025;)</td>
<td align="left" valign="top">1.0 (Ref)</td>
<td align="center" valign="top">5.31;0.07</td></tr>
<tr>
<td align="left" valign="top">&#x02003;AG (heterozygous)</td>
<td align="right" valign="top">70 (53.9&#x00025;)</td>
<td align="center" valign="top">76 (47.5&#x00025;)</td>
<td align="left" valign="top">1.99 (1.05&#x02013;3.74); <bold>0.03; 0.04</bold></td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;AA (variant)</td>
<td align="right" valign="top">41 (31.5&#x00025;)</td>
<td align="center" valign="top">43 (26.9&#x00025;)</td>
<td align="left" valign="top">2.05 (1.03&#x02013;4.10); <bold>0.03; 0.05</bold></td>
<td align="left" valign="top"/></tr>
<tr>
<td colspan="5" align="left" valign="top">Dominant inheritance</td></tr>
<tr>
<td align="left" valign="top">&#x02003;GG</td>
<td align="right" valign="top">19 (14.6&#x00025;)</td>
<td align="center" valign="top">41 (25.6&#x00025;)</td>
<td align="left" valign="top">1.0 (Ref)</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;AG &#x0002B; AA</td>
<td align="right" valign="top">111 (85.4&#x00025;)</td>
<td align="center" valign="top">119 (52.5&#x00025;)</td>
<td align="left" valign="top">2.01 (1.10&#x02013;3.68); <bold>0.02; 0.03</bold></td>
<td align="left" valign="top"/></tr>
<tr>
<td colspan="5" align="left" valign="top">Recessive inheritance</td></tr>
<tr>
<td align="left" valign="top">&#x02003;GG &#x0002B; AG</td>
<td align="right" valign="top">89 (68.5&#x00025;)</td>
<td align="center" valign="top">117 (73.1&#x00025;)</td>
<td align="left" valign="top">1.0 (Ref)</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;AA</td>
<td align="right" valign="top">41 (31.5&#x00025;)</td>
<td align="center" valign="top">43 (26.9&#x00025;)</td>
<td align="left" valign="top">1.25 (0.75&#x02013;2.08); 0.38; 0.44</td>
<td align="left" valign="top"/></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-mmr-07-03-0811">
<label>a</label>
<p>Pearson&#x02019;s p-value;</p></fn><fn id="tfn2-mmr-07-03-0811">
<label>b</label>
<p>Fisher&#x02019;s exact p-value; statistically significant p-values in bold. CRC, colorectal cancer.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tIII-mmr-07-03-0811" position="float">
<label>Table III</label>
<caption>
<p>Association between <italic>cyclin D1</italic> polymorphism and clinicopathological characteristics.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom"/>
<th colspan="4" align="center" valign="bottom">Cases<xref rid="tfn3-mmr-07-03-0811" ref-type="table-fn">a</xref></th>
<th align="center" valign="top"/></tr>
<tr>
<th align="left" valign="bottom"/>
<th colspan="4" align="left" valign="bottom">
<hr/></th>
<th align="center" valign="top"/></tr>
<tr>
<th align="left" valign="bottom">Variables</th>
<th align="center" valign="bottom">All cases<break/>n&#x0003D;130</th>
<th align="center" valign="bottom">GG<break/>19 (14.6&#x00025;)</th>
<th align="center" valign="bottom">AG<break/>70 (53.9&#x00025;)</th>
<th align="center" valign="bottom">AA<break/>41 (31.5&#x00025;)</th>
<th align="center" valign="top">P-value</th></tr></thead>
<tbody>
<tr>
<td colspan="6" align="left" valign="top">Age group</td></tr>
<tr>
<td align="left" valign="top">&#x02003;&#x02264;50</td>
<td align="center" valign="top">48 (36.9&#x00025;)</td>
<td align="right" valign="top">6</td>
<td align="center" valign="top">33</td>
<td align="right" valign="top">9</td>
<td align="right" valign="top">7.32; 0.035</td></tr>
<tr>
<td align="left" valign="top">&#x02003;&gt;50</td>
<td align="center" valign="top">82 (63.1&#x00025;)</td>
<td align="right" valign="top">13</td>
<td align="center" valign="top">37</td>
<td align="right" valign="top">32</td>
<td align="right" valign="top"/></tr>
<tr>
<td colspan="6" align="left" valign="top">Gender</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Female</td>
<td align="center" valign="top">54 (41.54&#x00025;)</td>
<td align="right" valign="top">8</td>
<td align="center" valign="top">27</td>
<td align="right" valign="top">19</td>
<td align="right" valign="top">0.65; 0.720</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Male</td>
<td align="center" valign="top">76 (58.46&#x00025;)</td>
<td align="right" valign="top">11</td>
<td align="center" valign="top">43</td>
<td align="right" valign="top">22</td>
<td align="right" valign="top"/></tr>
<tr>
<td colspan="6" align="left" valign="top">Dwelling</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Rural</td>
<td align="center" valign="top">91 (70.0&#x00025;)</td>
<td align="right" valign="top">11</td>
<td align="center" valign="top">57</td>
<td align="right" valign="top">23</td>
<td align="right" valign="top"><bold>9.45; 0.008</bold></td></tr>
<tr>
<td align="left" valign="top">&#x02003;Urban</td>
<td align="center" valign="top">39 (30.0&#x00025;)</td>
<td align="right" valign="top">8</td>
<td align="center" valign="top">13</td>
<td align="right" valign="top">18</td>
<td align="right" valign="top"/></tr>
<tr>
<td colspan="6" align="left" valign="top">Smoking status</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Ever</td>
<td align="center" valign="top">81 (62.3&#x00025;)</td>
<td align="right" valign="top">10</td>
<td align="center" valign="top">48</td>
<td align="right" valign="top">23</td>
<td align="right" valign="top">2.6; 0.272</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Never</td>
<td align="center" valign="top">49 (37.7&#x00025;)</td>
<td align="right" valign="top">9</td>
<td align="center" valign="top">22</td>
<td align="right" valign="top">18</td>
<td align="right" valign="top"/></tr>
<tr>
<td colspan="6" align="left" valign="top">Tumour location</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Colon</td>
<td align="center" valign="top">52 (40.0&#x00025;)</td>
<td align="right" valign="top">7</td>
<td align="center" valign="top">31</td>
<td align="right" valign="top">14</td>
<td align="right" valign="top">1.2; 0.548</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Rectum</td>
<td align="center" valign="top">78 (60.0&#x00025;)</td>
<td align="right" valign="top">12</td>
<td align="center" valign="top">39</td>
<td align="right" valign="top">27</td>
<td align="right" valign="top"/></tr>
<tr>
<td colspan="6" align="left" valign="top">Nodal status</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Involved</td>
<td align="center" valign="top">88 (67.7&#x00025;)</td>
<td align="right" valign="top">14</td>
<td align="center" valign="top">49</td>
<td align="right" valign="top">25</td>
<td align="right" valign="top">1.33; 0.514</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Not involved</td>
<td align="center" valign="top">42 (32.3&#x00025;)</td>
<td align="right" valign="top">5</td>
<td align="center" valign="top">21</td>
<td align="right" valign="top">16</td>
<td align="right" valign="top"/></tr>
<tr>
<td colspan="6" align="left" valign="top">Tumour grade</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Well-differentiated</td>
<td align="center" valign="top">98 (75.4&#x00025;)</td>
<td align="right" valign="top">15</td>
<td align="center" valign="top">54</td>
<td align="right" valign="top">29</td>
<td align="right" valign="top">0.72; 0.697</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Moderately/poorly differentiated</td>
<td align="center" valign="top">32 (24.6&#x00025;)</td>
<td align="right" valign="top">4</td>
<td align="center" valign="top">16</td>
<td align="right" valign="top">12</td>
<td align="right" valign="top"/></tr></tbody></table>
<table-wrap-foot><fn id="tfn3-mmr-07-03-0811">
<label>a</label>
<p>One was squamous cell carcinoma; Statistically significant p-values in bold.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
